Metabolic & Weight Management

Amycretin

Also known as NN-9487 · NN9487 · NNC0487-0111 · Zenagamtide · oral amycretin · subcutaneous amycretin

Emerging researchSubcutaneous injectionOralInvestigational only; not approved by the FDA or any other regulator for any use as of mid-2026. Amycretin is a proprietary Novo Nordisk investigational compound studied in clinical trials and is not a recognized ingredient for 503A or 503B pharmacy compounding, so there is no legal prescribing or compounding pathway for it in the United States; it is available only through authorized clinical trials. GLP-1 and amylin receptor agonists are not currently named on the WADA Prohibited List, so amycretin is not specifically prohibited for athletes, though as an unapproved investigational substance its use outside trials carries regulatory and anti-doping uncertainty.

Amycretin (international nonproprietary name zenagamtide) is an investigational peptide developed by Novo Nordisk that acts as a unimolecular (single-molecule) agonist at both the GLP-1 receptor and the amylin receptor, with a single peptide engineered to activate both targets. By engaging GLP-1 signaling (appetite regulation) and amylin signaling (satiety and metabolic regulation), it is being explored as a candidate for weight management and glycemic control, and it is notable for being studied in both oral and subcutaneous formulations. Phase 1b/2a (subcutaneous) and early oral trial data in people with overweight or obesity were published in The Lancet and presented at the ADA Scientific Sessions in 2025, and a Phase 2 trial in type 2 diabetes reported results in late 2025. Based on these results, Novo Nordisk has announced plans to advance amycretin into Phase 3 development for obesity and type 2 diabetes. The evidence base is therefore early-to-mid-stage human research, with no regulatory approval to date.

Studied / used for

Investigated for weight management in adults with overweight or obesity
Studied for glycemic control and HbA1c reduction in type 2 diabetes
Investigated for appetite and satiety regulation via combined GLP-1 and amylin receptor activation
Studied to compare oral versus subcutaneous delivery of a GLP-1/amylin agonist

Commonly reported side effects

Nausea (commonly reported)
Vomiting (commonly reported)
Decreased appetite (commonly reported)
Other gastrointestinal symptoms such as diarrhea or constipation (commonly reported)

Emerging research. Active research; human evidence still developing. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds